DBV Technologies SA
Company Profile
Business description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Contact
177-181 avenue Pierre Brossolette
Montrouge92120
FRAT: +33 155427878
E: investors@dbv-technologies.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
108
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,561.70 | 142.70 | -1.85% |
| CAC 40 | 6,961.83 | 138.59 | -1.95% |
| DAX 40 | 19,900.64 | 379.62 | -1.87% |
| Dow JONES (US) | 37,615.47 | 2,930.46 | -7.23% |
| FTSE 100 | 7,766.20 | 144.33 | -1.82% |
| HKSE | 20,323.58 | 195.90 | 0.97% |
| NASDAQ | 15,267.91 | 1,282.69 | -7.75% |
| Nikkei 225 | 31,714.03 | 1,298.55 | -3.93% |
| NZX 50 Index | 11,806.55 | 84.89 | -0.71% |
| S&P 500 | 4,977.73 | 84.52 | -1.67% |
| S&P/ASX 200 | 7,375.00 | 135.00 | -1.80% |
| SSE Composite Index | 3,186.81 | 41.26 | 1.31% |